Eledon Pharmaceuticals, Inc.
ELDN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.01 | -0.00 | 0.02 |
| FCF Yield | -23.64% | -89.20% | -87.27% | -44.24% |
| EV / EBITDA | -5.10 | -0.35 | 0.26 | 0.51 |
| Quality | ||||
| ROIC | -42.91% | -50.26% | 9.76% | -20.68% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.31 | 0.34 | 0.32 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -19.59% | -39.06% | 1.69% | -90.07% |
| Safety | ||||
| Net Debt / EBITDA | 0.55 | 0.04 | 0.64 | 2.29 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -5,930.49 | 0.00 | -2,152.82 | -3,393.56 |